Resistance Mechanisms in EGFR+ NSCLC Treatment - Targeted Therapies in Lung Cancer 2023

Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic ...Подробнее

Dr Abhinav Zawar | Mechanism Of Resistance To Osimeritinib In EGFR Mutated Lung Cancer | CRSFПодробнее

Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in NSCLCПодробнее

Personalized therapy for NSCLC: Biomarker testing, treatment and management in MET alterationsПодробнее

The Future of RET+ NSCLC Treatment - Targeted Therapies in Lung Cancer 2023Подробнее

EGFR Mutations in Advanced NSCLC - Targeted Therapies in Lung Cancer 2023Подробнее

EGFR: The Challenge of Primary and Secondary ResistanceПодробнее

S3 Episode 1: What Are the Latest Improvements in Targeted Therapy Options and Diagnostic Technol...Подробнее

2023 Best of Lung: Targeted Therapies in Lung CancerПодробнее

Future Research and Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient ForumПодробнее

Full Video OnDemand -Targeted Therapies Patient Forum 2022 - for those living with Lung CancerПодробнее

Full Event Mainstage 2023 Targeted Therapies in Lung Cancer Patient Forum ON-DEMANDПодробнее

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted TherapiesПодробнее

ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice ShawПодробнее

Precision Oncology in Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the WayПодробнее

Emerging Treatment Approaches for NSCLC And Head & Neck Cancer - 24 MayПодробнее

A Visual Exploration of New Targeted Therapies for EGFR Exon 20 Insertions in NSCLCПодробнее

Antibody Drug Conjugates for CancerПодробнее

Refining Biomarker Testing and Targeted Treatment of NSCLC With EGFR MutationsПодробнее